MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

Search

Charles River Laboratories International Inc

Închisă

SectorSănătate

219.06 0.06

Rezumat

Modificarea prețului

24h

Curent

Minim

214.89

Maxim

227.8

Indicatori cheie

By Trading Economics

Venit

2.9M

56M

Vânzări

-27M

1B

EPS

2.43

Marjă de profit

5.529

Angajați

18,700

EBITDA

-23M

198M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

-6.22% downside

Dividende

By Dow Jones

Următoarele câștiguri

18 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

1.5B

10B

Deschiderea anterioară

219

Închiderea anterioară

219.06

Sentimentul știrilor

By Acuity

50%

50%

173 / 370 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

Charles River Laboratories International Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 ian. 2026, 23:54 UTC

Market Talk

CBA Could Underperform Again in 2026 -- Market Talk

12 ian. 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 ian. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

12 ian. 2026, 23:43 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 ian. 2026, 23:18 UTC

Achiziții, Fuziuni, Preluări

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 ian. 2026, 21:56 UTC

Market Talk

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 ian. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 ian. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

12 ian. 2026, 21:50 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

12 ian. 2026, 21:18 UTC

Market Talk

Global Equities Roundup: Market Talk

12 ian. 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 ian. 2026, 20:54 UTC

Câștiguri

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 ian. 2026, 20:48 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 ian. 2026, 20:33 UTC

Market Talk

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 ian. 2026, 20:18 UTC

Achiziții, Fuziuni, Preluări

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 ian. 2026, 20:18 UTC

Achiziții, Fuziuni, Preluări

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 ian. 2026, 19:39 UTC

Market Talk

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 ian. 2026, 19:36 UTC

Market Talk

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 ian. 2026, 19:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 ian. 2026, 19:33 UTC

Market Talk

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 ian. 2026, 19:24 UTC

Achiziții, Fuziuni, Preluări

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 ian. 2026, 19:22 UTC

Achiziții, Fuziuni, Preluări

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 ian. 2026, 18:21 UTC

Achiziții, Fuziuni, Preluări

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 ian. 2026, 18:20 UTC

Achiziții, Fuziuni, Preluări

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 ian. 2026, 18:19 UTC

Market Talk

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 ian. 2026, 18:16 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 ian. 2026, 18:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12 ian. 2026, 18:09 UTC

Market Talk

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 ian. 2026, 18:01 UTC

Achiziții, Fuziuni, Preluări

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 ian. 2026, 18:00 UTC

Market Talk

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Comparație

Modificare preț

Charles River Laboratories International Inc Așteptări

Obiectiv de preț

By TipRanks

-6.22% jos

Prognoză pe 12 luni

Medie 202.1 USD  -6.22%

Maxim 225 USD

Minim 170 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCharles River Laboratories International Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

12 ratings

8

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

117.16 / 144.77Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

173 / 370 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat